OHK Medical Devices & Surgical Specialties to Launch Hemaclear® in Australia & New Zealand

Share Article

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile, exsanguinating tourniquet device, announced today that it has signed an agreement with Surgical Specialties Pty. to introduce HemaClear® to the Australia and New Zealand markets. This announcement comes as the latest step in the Company’s previously announced five year plan to enter the APAC markets.

Hemaclear

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it has further expanded its international business activity in the Asia Pacific region. The company has entered an exclusive agreement in Australia and New Zealand with Surgical Specialties Pty, as part of the Company’s five year plan to enter the APAC markets. OHK and Surgical Specialties will formally launch their entry into these markets at the Australian Orthopedic Association Annual Scientific Meeting to be held in Sydney between 7-11 of October, 2012 and at the New Zealand Orthopedic Association Annual Scientific Meeting to be held in Dunedin between 14-17 of October, 2012.

“We are very excited to enter these well developed markets and believe that the combination of an ideal partner and an exciting marketplace will prove to be a strong base for the introduction and adoption of HemaClear®”, said Oren Gavriely, CEO, OHK Medical Devices. Gavriely added that “The introduction of HemaClear in Australia and New Zealand will further base HemaClear® as a worldwide standard of care tourniquet technology for bloodless surgery, improving clinical outcomes and saving hospitals time and money.”

“HemaClear will be an exciting addition to our current product portfolio“, said Doug North, Managing Director, Surgical Specialties Pty. “This exciting tourniquet technology represents the first advance in tourniquets in more than 100 years and we look forward to introducing it to surgeons and hospital administrators throughout Australia and New Zealand,” North added.

About HemaClear®
HemaClear® is the original sterile, simple and effective single-use exsanguinating tourniquet. The device is comprised of a silicone band, sterile stockinet, and attached straps. Based upon our patented “grab and pull” method, HemaClear® is able to create a sterile and bloodless field within seconds. It is a cost effective device that replaces the need for extensive and expensive operating room equipment. HemaClear® has been proven successful and medically safe worldwide in over 500,000 surgical cases, both in the OR and in the field, including disaster-struck areas across the world. Founded in 2004, HemaClear® is manufactured by OHK based in Haifa, Israel, with representation in 20 countries covering over 2000 operating rooms. For more information about HemaClear®, visit http://www.hemaclear.com.

About Surgical Specialties
Established in 2005, Surgical Specialties’ vision is to own a reputation for excellence with its customers, suppliers and staff that its competitors aspire to. The Company’s mission is to help its customers improve their patient outcomes by providing excellent service in the distribution of innovative surgical products. Further to this, Surgical Specialties always aspires to exceed its supplier’s expectations with its partnership approach based on trust, reliability, communication and sales results. For more information visit: http://www.surgicalspecialties.com.au/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Grant Castor
Visit website